Creating advanced nanoparticles for targeted drug delivery
Official title: Computational Design of Antibody-Drug-Excipient Nanoparticles
Funded at Duke University · NIH-11054576 · Data updated 2026-11-12
This study is exploring new tiny particles that can carry medicine right to the parts of the body that need it most, making treatments safer and more effective, and it's designed for anyone interested in better ways to deliver medications.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $192,725 |
| NIH project number | 5R21EB034443-03 |
| Project ID | NIH-11054576 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with conditions that could benefit from targeted drug delivery systems, particularly those requiring innovative therapeutic approaches.
✕Less likely to help
Patients who are not seeking advanced therapeutic options or those with conditions that do not require targeted delivery may not benefit from this research.
What this research studies
This research focuses on developing innovative nanoparticles that can deliver medications directly to specific tissues in the body, enhancing their effectiveness and safety. By utilizing machine learning and novel synthesis techniques, the project aims to create drug-excipient co-aggregates that can carry a higher drug load and be tailored for targeted delivery. The researchers will validate these nanoparticles' targeting capabilities through laboratory and animal testing, ensuring they can effectively reach the intended sites of action.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for various conditions by improving how drugs are delivered in the body.
How similar studies have gone: Other research has shown promise in using machine learning and novel nanoparticle designs for drug delivery, indicating a potential for success in this innovative approach.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Reker, Daniel — Duke University
- Study coordinator: Reker, Daniel
Related research
Other NIH-funded projects on the same topics.
-
Investigating genetic factors in Lewy body diseases
This study is looking at how changes in a specific gene might play a role in conditions like Parkinson's disease and dementia, so that people can better understand how their genetics affect their health and possibly find more tailored treatments.
-
Targeting the PAX3-FOXO1 protein in a deadly childhood cancer
This study is looking at a specific protein that helps a tough childhood cancer called alveolar rhabdomyosarcoma, with the goal of finding new ways to treat kids who have this illness.
-
Improving population health by studying reproduction and development
This study is looking at how different things in our environment can impact pregnancy and the health of babies, and it’s for people who are planning to have children or are already parents, as it aims to help improve understanding and outcomes for everyone involved.
-
Modeling axon degeneration in C. elegans to help ALS patients
Researchers are using a tiny worm model to uncover how axons break down, which could point to new ways to help people with ALS and related nerve diseases.
-
Induced Suppression of Platelet Activity in Aneurysmal SAH Management
A new approach tests whether carefully reducing platelet activity can improve outcomes after aneurysmal subarachnoid hemorrhage.
-
AI-enhanced virtual reality tool to support remote emergency brain surgery training in Tanzania
A new AI-powered virtual reality tool helps non-experts in low-resource areas get real-time remote guidance for emergency traumatic brain injury surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.